Previous 10 | Next 10 |
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2019 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. ...
Neurocrine Biosciences (NASDAQ: NBIX ) is scheduled to announce Q3 earnings results on Monday, November 4th, after market close. The consensus EPS Estimate is $0.63 (+21.2% Y/Y) and the consensus Revenue Estimate is $211.31M (+39.2% Y/Y). Over the last 2 years, nbix has beaten EPS est...
SAN DIEGO , Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019 . Neurocrine will then host a conference call and webcast to discuss its fi...
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
SAN DIEGO , Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA ® (valbenazine) capsules in reducing abnormal movements in adults with tardive ...
SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA ® (valbenazine) in adults with tardive dyskinesia (TD), an involuntary movement disor...
SAN DIEGO , Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer. Boyer joins Neurocrine Biosciences from BGR Group, where he served as a ...
SAN DIEGO , Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA ® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatme...
Axovant Gene Therapies ( AXGT ) is running three clinical programs on three gene therapy candidates for neurological and developmental disorders. Readouts from all three programs are expected in Q4'19, presenting an opportunity for a trade, which is the focus of this article. A big Q4'19 u...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...